WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414009
CAS#: 123441-03-2 (free base)
Description: Rivastigmine, also known as S-Rivastigmine, is an orally active and potent cholinesterase (ChE) inhibitor. Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia, particularly Alzheimer's and dementia due to Parkinson's disease.
Hodoodo Cat#: H414009
Name: Rivastigmine free base
CAS#: 123441-03-2 (free base)
Chemical Formula: C14H22N2O2
Exact Mass: 250.17
Molecular Weight: 250.340
Elemental Analysis: C, 67.17; H, 8.86; N, 11.19; O, 12.78
Related CAS #: 123441-03-2 (free base) 129101-54-8 (tartrate)
Synonym: Rivastigmine Free Base; ENA713; ENA 713; ENA-713; S-Rivastigmine
IUPAC/Chemical Name: (S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
InChi Key: XSVMFMHYUFZWBK-NSHDSACASA-N
InChi Code: InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
SMILES Code: O=C(OC1=CC=CC([C@@H](N(C)C)C)=C1)N(CC)C
Appearance: Liquid
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 250.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3. PMID: 25858345.
2: Kandiah N, Pai MC, Senanarong V, Looi I, Ampil E, Park KW, Karanam AK, Christopher S. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. PMID: 28458525; PMCID: PMC5402908.
3: Espay AJ, Marsili L, Mahajan A, Sturchio A, Pathan R, Pilotto A, Elango DS, Pezous N, Masellis M, Gomez-Mancilla B. Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Ann Neurol. 2021 Jan;89(1):91-98. doi: 10.1002/ana.25923. Epub 2020 Oct 20. PMID: 33016374.
4: Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging. 2008;3(2):211-25. PMID: 18686744; PMCID: PMC2546466.
5: Sang Z, Wang K, Shi J, Cheng X, Zhu G, Wei R, Ma Q, Yu L, Zhao Y, Tan Z, Liu W. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease. Eur J Med Chem. 2020 Feb 1;187:111958. doi: 10.1016/j.ejmech.2019.111958. Epub 2019 Dec 16. PMID: 31865014.
6: Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Mar;15(3):249-58. doi: 10.1016/S1474-4422(15)00389-0. Epub 2016 Jan 13. PMID: 26795874.
7: Monji A. [Rivastigmine]. Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:36-40. Japanese. PMID: 22755152.
8: Chou PS, Jhang KM, Huang LC, Wang WF, Yang YH. Skinfold thickness for rivastigmine patch application in Alzheimer's disease. Psychopharmacology (Berl). 2019 Apr;236(4):1255-1260. doi: 10.1007/s00213-018-5135-x. Epub 2019 Jan 15. PMID: 30645680.
9: Siddiqui MA, Wagstaff AJ. Rivastigmine: in Parkinson's disease dementia. CNS Drugs. 2006;20(9):739-47; discussion 748-50. doi: 10.2165/00023210-200620090-00003. PMID: 16953649.
10: Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract. 2010 Apr;64(5):651-60. doi: 10.1111/j.1742-1241.2009.02330.x. Epub 2010 Jan 19. PMID: 20102418.